Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
Adult
Aged
Benzoates
Hematologic Agents
/ therapeutic use
Humans
Hydrazines
Medicare
Platelet Count
Purpura, Thrombocytopenic, Idiopathic
/ chemically induced
Receptors, Fc
/ therapeutic use
Receptors, Thrombopoietin
/ agonists
Recombinant Fusion Proteins
/ therapeutic use
Retrospective Studies
Thrombopoietin
/ adverse effects
United States
/ epidemiology
Administrative claims
Discontinuation
Eltrombopag
Immune thrombocytopenia
Medical chart review
Observational
Platelet response
Retrospective study
Romiplostim
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
07
12
2021
accepted:
04
06
2022
pubmed:
19
7
2022
medline:
17
8
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Administrative claims provide a rich data source for retrospective studies of real-world clinical practice, yet some important data may be inconsistent or unavailable. This study explored factors influencing discontinuation of thrombopoietin receptor agonists (TPO-RAs) among patients with immune thrombocytopenia (ITP), by adding medical chart abstraction for additional details. Adult (≥ 18 years) patients with continuous commercial or Medicare Advantage with Part D health insurance coverage were included. Inclusion criteria were ≥ 1 claim for eltrombopag or romiplostim and ≥ 2 diagnoses of ITP between December 31, 2017, and January 1, 2020. Providers were asked to provide access to medical charts for abstraction. The analyses included only patients who discontinued TPO-RA and described patient characteristics, treatment patterns, platelet values, and reasons for discontinuation. Among 207 ITP patients treated with a TPO-RA, 137 (66%) discontinued treatment during the observation period. The mean TPO-RA treatment duration was 185 days. Mean platelet count at the time of discontinuation was 197 × 10
Identifiants
pubmed: 35849155
doi: 10.1007/s00277-022-04888-7
pii: 10.1007/s00277-022-04888-7
doi:
Substances chimiques
Benzoates
0
Hematologic Agents
0
Hydrazines
0
Receptors, Fc
0
Receptors, Thrombopoietin
0
Recombinant Fusion Proteins
0
Thrombopoietin
9014-42-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1915-1924Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829–3866. https://doi.org/10.1182/bloodadvances.2019000966
doi: 10.1182/bloodadvances.2019000966
pubmed: 31794604
pmcid: 6963252
Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160(11):1630–1638. https://doi.org/10.1001/archinte.160.11.1630
doi: 10.1001/archinte.160.11.1630
pubmed: 10847256
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393. https://doi.org/10.1182/blood-2008-07-162503
doi: 10.1182/blood-2008-07-162503
pubmed: 19005182
McMillan R, Bussel JB, George JN, Lalla D, Nichol JL (2008) Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 83(2):150–154. https://doi.org/10.1002/ajh.20992
doi: 10.1002/ajh.20992
pubmed: 17722072
Newton JL, Reese JA, Watson SI, Vesely SK, Bolton-Maggs PH, George JN, Terrell DR (2011) Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol 86(5):420–429. https://doi.org/10.1111/j.1600-0609.2011.01587.x
doi: 10.1111/j.1600-0609.2011.01587.x
pubmed: 21323737
Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113(26):6511–6521. https://doi.org/10.1182/blood-2009-01-129155
doi: 10.1182/blood-2009-01-129155
pubmed: 19395674
pmcid: 2710913
Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85(3):174–180. https://doi.org/10.1002/ajh.21616
doi: 10.1002/ajh.21616
pubmed: 20131303
Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9(5):A342-349. https://doi.org/10.1016/j.autrev.2009.11.020
doi: 10.1016/j.autrev.2009.11.020
pubmed: 19945546
Fogarty PF (2009) Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am 23(6):1213–1221. https://doi.org/10.1016/j.hoc.2009.08.004
doi: 10.1016/j.hoc.2009.08.004
pubmed: 19932429
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3:3780–3817. https://doi.org/10.1182/bloodadvances.2019000812
doi: 10.1182/bloodadvances.2019000812
pubmed: 31770441
pmcid: 6880896
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377(9763):393–402. https://doi.org/10.1016/S0140-6736(10)60959-2
doi: 10.1016/S0140-6736(10)60959-2
pubmed: 20739054
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, ArningM (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double‐blind, placebo-controlled trial. Lancet 373(9664):641‐648. https://doi.org/10.1016/S0140-6736(09)60402-5
Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M (2017) Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol 176(1):101–110. https://doi.org/10.1111/bjh.14380
doi: 10.1111/bjh.14380
pubmed: 27734464
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610):395–403. https://doi.org/10.1016/S0140-6736(08)60203-2
doi: 10.1016/S0140-6736(08)60203-2
pubmed: 18242413
Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M (2016) Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10039):45–54. https://doi.org/10.1016/S0140-6736(16)00279-8
doi: 10.1016/S0140-6736(16)00279-8
pubmed: 27103127
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R (2011) Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 94(1):71–80. https://doi.org/10.1007/s12185-011-0886-8
doi: 10.1007/s12185-011-0886-8
pubmed: 21706145
Newland A, Godeau B, Priego V (2016) Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol 172(2):262–273. https://doi.org/10.1111/bjh.13827
doi: 10.1111/bjh.13827
pubmed: 26537623
Al-Samkari H, Nagalla S (2021) Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets :1–8. https://doi.org/10.1080/09537104.2021.1881952
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113(10):2161–2171. https://doi.org/10.1182/blood-2008-04-150078
doi: 10.1182/blood-2008-04-150078
pubmed: 18981291
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130(23):2527–2536. https://doi.org/10.1182/blood-2017-04-748707
doi: 10.1182/blood-2017-04-748707
pubmed: 29042367
González-López TJ, Pascual C, Alvarez-Roman MT (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90(3):E40-43. https://doi.org/10.1002/ajh.23900
doi: 10.1002/ajh.23900
pubmed: 25400215
Červinek L, Mayer J, Doubek M (2015) Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol 102(1):7–11. https://doi.org/10.1007/s12185-015-1793-1
doi: 10.1007/s12185-015-1793-1
pubmed: 25833724
Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, Patriarca A, Carli G, Barcellini W, Celli M, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Paoloni F, Gigliotti CL, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F; for Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) (2021) Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol 192(2):386–396. https://doi.org/10.1111/bjh.17334
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682. https://doi.org/10.1093/aje/kwq433
doi: 10.1093/aje/kwq433
pubmed: 21330339
Cooper N, Hill Q, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A (2021) Real-world tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified Delphi Panel. Acta Haematol 144(4):418–426. https://doi.org/10.1159/000510676
doi: 10.1159/000510676
pubmed: 33789275
Ghadaki B, Nazi I, Kelton JG, Arnold DM (2013) Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 53(11):2807–2812. https://doi.org/10.1111/trf.12139
doi: 10.1111/trf.12139
pubmed: 23451917
pmcid: 3938454
Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, Michel M (2014) The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 165(6):865–869. https://doi.org/10.1111/bjh.12888
doi: 10.1111/bjh.12888
pubmed: 24725224
Iino M, Sakamoto Y, Sato T (2020) Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice. Intl J Hematol 112(2):159–168. https://doi.org/10.1007/s12185-020-02893-y
doi: 10.1007/s12185-020-02893-y
Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B (2011) Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 118(16):4338-4345. https://doi.org/10.1182/blood-2011-03-340166
Lal LS, Said Q, Andrade K, Cuker A (2020) Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records. Res Pract Thromb Haemost 4(7):1131–1140. https://doi.org/10.1002/rth2.12423
doi: 10.1002/rth2.12423
pubmed: 33134779
pmcid: 7590333